Cargando…
Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen
BACKGROUND: Lipid abnormalities are prevalent among people living with human immunodeficiency virus (HIV) (PLWH) and contribute to increasing risk of cardiovascular events. This study aims to investigate the incidence of dyslipidemia and its risk factors in PLWH after receiving different first-line...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631593/ https://www.ncbi.nlm.nih.gov/pubmed/33273329 http://dx.doi.org/10.1097/CM9.0000000000001245 |
_version_ | 1785132395082547200 |
---|---|
author | Sun, Li-Qin Liu, Jia-Ye He, Yun Zhou, Yang Xu, Liu-Mei Zhang, Lu-Kun Zhao, Fang Liu, Xiao-Ning Song, Ying Cao, Ting-Zhi Tian, Yi-Mei Rao, Man Wang, Hui |
author_facet | Sun, Li-Qin Liu, Jia-Ye He, Yun Zhou, Yang Xu, Liu-Mei Zhang, Lu-Kun Zhao, Fang Liu, Xiao-Ning Song, Ying Cao, Ting-Zhi Tian, Yi-Mei Rao, Man Wang, Hui |
author_sort | Sun, Li-Qin |
collection | PubMed |
description | BACKGROUND: Lipid abnormalities are prevalent among people living with human immunodeficiency virus (HIV) (PLWH) and contribute to increasing risk of cardiovascular events. This study aims to investigate the incidence of dyslipidemia and its risk factors in PLWH after receiving different first-line free antiretroviral regimens. METHODS: PLWH who sought care at the Third People's Hospital of Shenzhen from January 2014 to December 2018 were included, and the baseline characteristics and clinical data during the follow-up were collected, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The risk factors of dyslipidemia after antiretroviral therapy were analyzed with the generalized estimating equation model. RESULTS: Among the 7623 PLWH included, the mean levels of TC, HDL-C and LDL-C were 4.23 ± 0.85 mmol/L, 1.27 ± 0.29 mmol/L and 2.54 ± 0.65 mmol/L, respectively, and the median TG was 1.17 (IQR: 0.85−1.68) mmol/L. Compared with that in PLWH receiving tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + ritonavir-boosted lopinavir (LPV/r), zidovudine (AZT) + 3TC + efavirenz (EFV), and AZT + 3TC + LPV/r, the incidence of dyslipidemia was lower in PLWH receiving TDF + 3TC + EFV. In multivariate analysis, we found that the risks of elevations of TG, TC, and LDL-C were higher with TDF + 3TC + LPV/r (TG: odds ratio [OR] = 2.82, 95% confidence interval [CI]: 2.55−3.11, P < 0.001; TC: OR = 1.24, 95% CI: 1.14−1.35, P < 0.001; LDL: OR = 1.06, 95% CI: 1.00−1.12, P = 0.041), AZT + 3TC + EFV (TG: OR = 1.41, 95% CI: 1.28−1.55, P < 0.001; TC: OR = 1.43, 95% CI: 1.31−1.56, P < 0.001; LDL: OR = 1.18, 95% CI: 1.12−1.25, P < 0.001), and AZT + 3TC + LPV/r (TG: OR = 3.08, 95% CI: 2.65−3.59, P < 0.001; TC: OR = 2.40, 95% CI: 1.96−2.94, P < 0.001; LDL: OR = 1.52, 95% CI: 1.37−1.69, P < 0.001) than with TDF + 3TC + EFV, while treatment with TDF + 3TC + LPV/r was less likely to restore HDL-C levels compared with TDF + 3TC + EFV (OR = 0.95, 95% CI: 0.92−0.97, P < 0.001). In addition to antiretroviral regimens, antiretroviral therapy duration, older age, overweight, obesity and other traditional factors were also important risk factors for dyslipidemia. CONCLUSION: The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China. |
format | Online Article Text |
id | pubmed-10631593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106315932020-12-05 Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen Sun, Li-Qin Liu, Jia-Ye He, Yun Zhou, Yang Xu, Liu-Mei Zhang, Lu-Kun Zhao, Fang Liu, Xiao-Ning Song, Ying Cao, Ting-Zhi Tian, Yi-Mei Rao, Man Wang, Hui Chin Med J (Engl) Original Articles BACKGROUND: Lipid abnormalities are prevalent among people living with human immunodeficiency virus (HIV) (PLWH) and contribute to increasing risk of cardiovascular events. This study aims to investigate the incidence of dyslipidemia and its risk factors in PLWH after receiving different first-line free antiretroviral regimens. METHODS: PLWH who sought care at the Third People's Hospital of Shenzhen from January 2014 to December 2018 were included, and the baseline characteristics and clinical data during the follow-up were collected, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The risk factors of dyslipidemia after antiretroviral therapy were analyzed with the generalized estimating equation model. RESULTS: Among the 7623 PLWH included, the mean levels of TC, HDL-C and LDL-C were 4.23 ± 0.85 mmol/L, 1.27 ± 0.29 mmol/L and 2.54 ± 0.65 mmol/L, respectively, and the median TG was 1.17 (IQR: 0.85−1.68) mmol/L. Compared with that in PLWH receiving tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + ritonavir-boosted lopinavir (LPV/r), zidovudine (AZT) + 3TC + efavirenz (EFV), and AZT + 3TC + LPV/r, the incidence of dyslipidemia was lower in PLWH receiving TDF + 3TC + EFV. In multivariate analysis, we found that the risks of elevations of TG, TC, and LDL-C were higher with TDF + 3TC + LPV/r (TG: odds ratio [OR] = 2.82, 95% confidence interval [CI]: 2.55−3.11, P < 0.001; TC: OR = 1.24, 95% CI: 1.14−1.35, P < 0.001; LDL: OR = 1.06, 95% CI: 1.00−1.12, P = 0.041), AZT + 3TC + EFV (TG: OR = 1.41, 95% CI: 1.28−1.55, P < 0.001; TC: OR = 1.43, 95% CI: 1.31−1.56, P < 0.001; LDL: OR = 1.18, 95% CI: 1.12−1.25, P < 0.001), and AZT + 3TC + LPV/r (TG: OR = 3.08, 95% CI: 2.65−3.59, P < 0.001; TC: OR = 2.40, 95% CI: 1.96−2.94, P < 0.001; LDL: OR = 1.52, 95% CI: 1.37−1.69, P < 0.001) than with TDF + 3TC + EFV, while treatment with TDF + 3TC + LPV/r was less likely to restore HDL-C levels compared with TDF + 3TC + EFV (OR = 0.95, 95% CI: 0.92−0.97, P < 0.001). In addition to antiretroviral regimens, antiretroviral therapy duration, older age, overweight, obesity and other traditional factors were also important risk factors for dyslipidemia. CONCLUSION: The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China. Lippincott Williams & Wilkins 2020-12-05 2020-11-09 /pmc/articles/PMC10631593/ /pubmed/33273329 http://dx.doi.org/10.1097/CM9.0000000000001245 Text en Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Articles Sun, Li-Qin Liu, Jia-Ye He, Yun Zhou, Yang Xu, Liu-Mei Zhang, Lu-Kun Zhao, Fang Liu, Xiao-Ning Song, Ying Cao, Ting-Zhi Tian, Yi-Mei Rao, Man Wang, Hui Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title | Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title_full | Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title_fullStr | Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title_full_unstemmed | Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title_short | Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen |
title_sort | evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in shenzhen |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631593/ https://www.ncbi.nlm.nih.gov/pubmed/33273329 http://dx.doi.org/10.1097/CM9.0000000000001245 |
work_keys_str_mv | AT sunliqin evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT liujiaye evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT heyun evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT zhouyang evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT xuliumei evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT zhanglukun evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT zhaofang evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT liuxiaoning evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT songying evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT caotingzhi evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT tianyimei evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT raoman evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen AT wanghui evolutionofbloodlipidsandriskfactorsofdyslipidemiaamongpeoplelivingwithhumanimmunodeficiencyviruswhohadreceivedfirstlineantiretroviralregimensfor3yearsinshenzhen |